INTRODUCTION
============

Arginine vasopressin (AVP) is an antidiuretic hormone which is synthesized in the magnocellular neurons of the supraoptic (SON) and paraventricular nuclei (PVN) in the hypothalamus. AVP is transported to the posterior pituitary through the axons, released into the systemic circulation, and plays a pivotal role in water balance by promoting reabsorption of free water through the V2 receptor in kidney. The release and synthesis of AVP are mainly regulated by plasma osmolality (or serum Na) in physiological conditions. The osmoregulation of the AVP neuron system is so precise that only 1--2% increases in serum Na levels significantly stimulate its release as well as the transcription of AVP gene in the SON and PVN.^[@ref1])^ Serum Na levels are thus maintained around 140 mEq/L, the threshold level for AVP release.

The deficiency of AVP leads to hypotonic polyuria, a disorder called neurohypophysial or central diabetes insipidus (hereafter, we use CDI as the abbreviation). Water intake also increases in order to maintain water balance in patients with CDI, as long as their thirst sensation remains intact.

In this review, the etiology, diagnosis, pathophysiology, treatment and prognosis of CDI are described.

ETIOLOGY
========

Most causes of CDI are acquired, and its prevalence of CDI is reportedly 1:25,000.^[@ref2])^ [Table 1](#table1){ref-type="table"} indicates the etiology of 165 Japanese patients with CDI we reported previously.^[@ref3])^ The most frequent cause of CDI is the tumors in the central nervous system (CNS) including craniopharyngioma and germ cell tumors, which could damage the AVP neuron system. CDI is also caused by inflammatory diseases such as lymphocytic infundibulo-neurohypophysitis (LINH) and IgG4-related disease. CDI often manifests after pituitary surgery. In this case, polyuria appears in the first 2 days after surgery and sometimes resolves spontaneously, although it could persist permanently if AVP neurons are damaged substantially.^[@ref4])^ Idiopathic CDI, 13% of total CDI in [Table 1](#table1){ref-type="table"}, is diagnosed when the causes of CDI are unclear. It is of note that LINH has been sometimes regarded as idiopathic CDI in some studies. This is probably because LINH is reported to be a possible underlying cause of idiopathic CDI.^[@ref5])^ The rates of idiopathic CDI among total CDI thus vary among studies. Although rare, CDI also occurs genetically. This subclass of CDI is called familial neurohypophysial diabetes insipidus (FNDI), which is inherited mostly in an autosomal dominant mode.^[@ref6])^ More than 80 mutations that cause FNDI have been reported so far,^[@ref7]-[@ref27])^ and they are mainly located in the coding region of neurophysin II, a carrier protein of AVP, in the gene locus ([Table 2](#table2){ref-type="table"}).

###### 

Etiology of patients with CDI

  Causes                     No. of Patients (%)
  -------------------------- ---------------------
  idiopathic                 i22 (13)
  igerm cell tumor of CNS    i38 (23)
  icraniopharyngioma         i32 (19)
  ineurosurgery              i21 (13)
  iinflammation              i15 (9)
  imetastasis to pituitary   i10 (6)
  iRathoke's cleft cyst      i6 (4)
  iempty sella syndrome      i4 (2)
  ipituitary adenoma         i4 (2)
  icardiac arrest            i4 (2)
  imalformation              i2 (1)
  iother                     i7 (4)
  total                      165 (100)

CNS, central nervous system. "Inflammation" includes lymphocytic infundibulo-neurohypophysitis and IgG4 related diseases.

###### 

Mutations causing FNDI

       Nucleotide Change            Exon       Amino Acid Change   Peptide   Japanese   Reference
  ---- ---------------------------- ---------- ------------------- --------- ---------- -----------
  1    c\. -33_4del                 1          p\. M1_T4del \*     SP1_4                7
  2    c\. -3A\>C                   1          p\. M1_T4del \*     SP1_4                8
  3    c\. 1A\>G                    1          p\. M1_T4del \*     SP1_4                9
  4    c\. 2delT                    1          p\. M1_T4del \*     SP1_4                10
  5    c\. 3delG                    1          p\. M1_T4del \*     SP1_4                9
  6    c\. 3G\>A                    1          p\. M1_T4del \*     SP1_4                9
  7    c\. 50C\>T                   1          p\. S17F            SP17                 9
  8    c\. 50C\>A                   1          p\. S17Y            SP17                 10
  9    c\. 52_54delTCC              1          p\. S18del          SP18                 11
  10   c\. 55G\>A                   1          p\. A19T            SP19      ✔          9
  11   c\. 56C\>T                   1          p\. A19V            SP19      ✔          9
  12   c\. 61T\>C                   1          p\. Y21H            AVP2                 9
  13   c\. 62A\>C                   1          p\. Y21S            AVP2      ✔          12
  14   c\. 64_66delTTC              1          p\. F22del          AVP3                 9
  15   c\. 77C\>T †                 1          p\. P26L            AVP7                 9
  16   c\. 123C\>G                  2          p\. C41W            NP10                 13
  17   c\. 127C\>G                  2          p\. P43A            NP12                 10
  18   c\. 132C\>A                  2          p\. C44W            NP13                 14
  19   c\. 133G\>C                  2          p\. G45R            NP14                 9
  20   c\. 133G\>T                  2          p\. G45C            NP14                 15
  21   c\. 143G\>T                  2          p\. G48V            NP17                 9
  22   c\. 151C\>T                  2          p\. R51C            NP20                 9
  23   huge deletion (AVP-OT) † ‡   2_3        p\. R51fs           NP20                 16
  24   c\. 154T\>C                  2          p\. C52R            NP21                 9
  25   c\. 160G\>C                  2          p\. G54R            NP23                 9
  26   c\. 160G\>A                  2          p\. G54R            NP23                 9
  27   c\. 161G\>T                  2          p\. G54V            NP23                 9
  28   c\. 161G\>A                  2          p\. G54E            NP23                 17
  29   c\. 164C\>T                  2          p\. P55L            NP24                 9
  30   c\. 164C\>A                  2          p\. P55H            NP24                 18
  31   c\. 173G\>T                  2          p\. C58F            NP27                 9
  32   c\. 175T\>C                  2          p\. C59R            NP28                 9
  33   c\. 176G\>A                  2          p\. C59Y            NP28                 9
  34   c\. 177_179delCGC            2          p\. C59delA60W      NP28_29              9
  35   c\. 188T\>C                  2          p\. L63P            NP32                 19
  36   c\. 193T\>A                  2          p\. C65S            NP34                 20
  37   c\. 194G\>T                  2          p\. C65F            NP34                 21
  38   c\. 200T\>C                  2          p\. V67A            NP36                 9
  39   c\. 207_209delGGC            2          p\. T69delA70T      NP38_39              22
  40   c\. 230_232delAGG            2          p\. E78del          NP47      ✔          29
  41   c\. 232G\>A                  2          p\. E78K            NP47      ✔          9
  42   c\. 232_234delGAG            2          p\. E78del          NP47                 23
  43   c\. 233A\>G                  2          p\. E78G            NP47                 9
  44   c\. 242T\>C                  2          p\. L81P            NP50                 9
  45   c\. 251C\>T                  2          p\. P84L            NP53                 24
  46   c\. 260C\>T                  2          p\. S87F            NP56                 9
  47   c\. 260C\>A                  2          p\. S87Y            NP56                 21
  48   c\. 262G\>A                  2          p\. G88S            NP57      ✔          9
  49   c\. 262G\>C                  2          p\. G88R            NP57                 9
  50   c\. 262G\>T                  2          p\. G88V            NP57                 25
  51   c\. 274T\>A                  2          p\. C92S            NP61                 21
  52   c\. 275G\>C                  2          p\. C92S            NP61                 9
  53   c\. 275G\>A                  2          p\. C92Y            NP61                 9
  54   c\. 276C\>A                  2          p\. C92X            NP61                 9
  55   c\. 276C\>G                  2          p\. C92W            NP61                 13
  56   c\. 277G\>T                  2          p\. G93W            NP62      ✔          9
  57   c\. 286G\>T                  2          p\. G96C            NP65                 9
  58   c\. 287G\>T                  2          p\. G96V            NP65      ✔          9, 26
  59   c\. 287G\>A                  2          p\. G96D            NP65                 9
  60   c\. 289C\>T                  2          p\. R97C            NP66                 9
  61   c\. 290G\>C                  2          p\. R97P            NP66                 9
  62   c\. 292T\>G                  2          p\. C98G            NP67                 9
  63   c\. 292T\>A                  2          p\. C98S            NP67                 9
  64   c\. 293_294GC\>CT            2          p\. C98S            NP67                 9
  65   c\. 294C\>A                  2          p\. C98X            NP67      ✔          9
  66   c\. 295G\>C                  2          p\. A99P            NP68                 9
  67   c\. 298G\>C                  2          p\. A100P           NP69                 18
  68   c\. 310T\>G                  2          p\. C104G           NP73                 9
  69   c\. 311G\>T                  2          p\. C104F           NP73                 9
  70   c\. 313T\>C                  2          p\. C105R           NP74                 9
  71   c\. 314G\>A                  2          p\. C105Y           NP74      ✔          9
  72   c\. 314G\>C                  2          p\. C105S           NP74                 14
  73   c\. 322G\>T                  2          p\. ?/E108X §       NP77                 27
  74   c\. 322+1delG                Intron 2   p\. E108fs \|\|     NP77                 9
  75   c\. 329G\>A                  3          p\. C110Y           NP79                 10
  76   c\. 330C\>A                  3          p\. C110X           NP79                 9
  77   c\. 337G\>T                  3          p\. E113X           NP82                 9
  78   c\. 342_343CG\>GT            3          p\. E115X           NP84                 9
  79   c\. 343G\>T                  3          p\. E115X           NP84                 9
  80   c\. 346T\>G                  3          p\. C116G           NP85                 9
  81   c\. 346T\>C                  3          p\. C116R           NP85                 9
  82   c\. 348C\>G                  3          p\. C116W           NP85                 9
  83   c\. 352G\>T                  3          p\. E118X           NP87                 9

\*, Mutations affecting the initiator ATG are predicted to result in translation initiation at an alternative downstream ATG (codon 5), causing a deletion of the first 4 amino acid residues. †, Mutations associated with autosomal-recessive inheritance of FNDI. ‡, 10,396 base pair deletion involving the majority of the AVP gene as well as its regulatory sequences in the intergenic region between the AVP and the oxytocin gene. §, This mutation site is the final base of exon 2. If splicing of intron 2 is affected, the entire (in-frame) intron is inserted into the mRNA leading to an insertion of 58 amino acids into the AVP protein (p.?). If splicing is not affected, this mutation causes to change codon 108 to a premature termination codon (p. E108X). \|\|, This mutation is predicted to cause retention of intron 2 during splicing. This will cause a frameshift from codon 108. ✔, Mutations reported in Japan.

DIAGNOSIS
=========

CDI is characterized by hypotonic polyuria accompanied by polydipsia, as long as the thirst sensation is intact. Daily urine volumes exceed 3 liters in most cases. Daily water intake, which could be estimated by asking the subjects how many cups of water they take every day, is almost equal to daily urine volumes. If daily water intake seems to be less than 2 liters, the subjects are unlikely to have CDI. It is also important to ask the subjects how often they urinate and drink water at night, because only daytime polydipsia and polyuria suggest psychologic polydipsia rather than CDI. Information intake from the subjects is thus useful for the screening of CDI.

Final diagnosis of CDI is made by confirming that AVP release is hampered in response to increases in plasma osmolality or serum Na levels. For this reason, either injection of hypertonic saline or the water restriction test is performed. In the hypertonic saline examination, 5% NaCl at the rate of 0.05 ml/kg body weight (BW) /min is injected intravenously for 2 hours, and the serum Na and plasma AVP levels are measured before and every 30 minutes after starting the injection. The serum Na levels usually increase approximately by 10 mEq/L, and plasma AVP levels are increased in proportion to the increases in serum Na levels in normal subjects. In contrast, increases in AVP release are blunted or even abolished in patients with CDI ([Figure 1](#fig1){ref-type="fig"}). To perform this examination, it is essential to use a sensitive assay for plasma AVP.

![Plasma AVP and serum Na levels in response to hypertonic saline injection. In normal subjects, plasma AVP levels increase in proportion to increases in serum Na levels. In CDI patients, the response of AVP is abolished. Note that serum Na levels are around 140 mEq/L in normal subjects but around 145 mEq/L in CDI patients before hypertonic saline injection.](2186-3326-78-0349-g001){#fig1}

In case no sensitive assays for plasma AVP are available, the water restriction test is performed. The subjects are deprived of water and food for about 6 hours or until their BW is decreased by 3%. In normal subjects, urine osmolality increases to levels more than 300 mOsm/kg. In contrast, urine osmolality remains to be below 300 mOsm/kg during the test in CDI patients. Injection of pitressin (vasopressin) at the end of the test could differentiate nephrogenic DI from CDI: urine osmolality increases in response to pitressin in patients with CDI but not in those with nephrogenic DI.

Pituitary MRI is also useful for the diagnosis of CDI. The high intensity in posterior pituitary in T1-weighted MRI images, which reportedly reflects the stock of pituitary AVP,^[@ref28])^ is observed in normal but not CDI subjects. However, as the AVP stock in the posterior pituitary could be decreased under chronically dehydrated conditions,^[@ref29])^ the lack of the high signal in T1-weighted pituitary MRI images is not specific to CDI. Pituitary MRI is also useful for the differential diagnosis of primary and secondary CDI. In case there is no abnormality except for the lack of the high signal in T1-weighted images, the subjects are diagnosed as idiopathic CDI. However, the follow-up of the imaging is necessary, particularly in children, since some abnormalities such as tumors in the CNS may appear later on.

PATHOPHYSIOLOGY
===============

Due to the lack of AVP action on V2 receptors in kidney, patients with CDI show hypotonic polyuria and polydipsia. The amount of daily urine volume as well as water intake could exceed 10 liters when AVP release is almost completely abolished. In this situation, patients must urinate and drink water almost every 1--2 hours. Normal subjects feel thirsty when serum Na levels exceed 145 mEq/L, while the threshold of serum Na levels for AVP release is around 140 mEq/L. This would explain why serum Na levels are always kept around 140 mEq/L in normal subjects whereas they are around 145 mEq/L in CDI patients, in whom the action of AVP is lacking. Thus, CDI patients consume water until their thirst sensation ceases, but they will soon feel thirsty because serum Na levels exceed 145 mEq/L again due to the lack of AVP action. If the function of osmoreceptors in hypothalamus is also lost, the patients would not feel thirsty even if the serum Na levels exceed 145 mEq/L. In other words, they are adipsic and could show severe hypernatremia.

Patients with CDI sometimes have dysfunction of the anterior pituitary as well. If adrenal insufficiency exists, urine volumes could decrease in CDI patients. This is called "masked DI," and substitution of adrenocortical hormones leads to increases in urine volume in patients with CDI accompanied by adrenal insufficiency. While several mechanisms have been suggested for masked DI, one possibility is that AVP release, which is usually inhibited by adrenocortical hormones, is stimulated from the residual AVP neurons in CDI patients with adrenal insufficiency. However, it is still controversial whether or not glucocorticoid receptors are expressed in the AVP neurons.^[@ref30])^

FNDI patients are born with normal water balance, but manifest progressive polyuria and polydipsia several months or years after birth.^[@ref31])^ The analyses of animal models for FNDI have demonstrated that accumulation of mutant AVP precursors in the endoplasmic reticulum (ER) causes ER stress and dysfunction of the neurons, which finally lead to loss of AVP neurons.^[@ref31]-[@ref33])^ This is consistent with autopsy studies which showed that magnocellular neurons were lost in patients with FNDI.^[@ref34])^

TREATMENT
=========

Desmopressin, an analogue of AVP, is used for the treatment of CDI. The desmopressin formula is either intranasal liquid, intranasal spray, or tablets. In Japan, an oral disintegrating tablet (ODT)^[@ref35])^ was approved for the treatment of CDI in 2012, and the QOL of CDI patients has reportedly been improved by ODT.^[@ref36])^ Our study also showed that the incidence of hyponatremia in CDI patients treated with desmopressin is decreased after the switch from the nasal formula to ODT.^37)^ This is probably due to the fact that the absorption and efficacy of ODT are more stable than those of the nasal formula, making it easier to determine the required dose of desmopressin. Nevertheless, one should be aware that there is still a high incidence of hyponatremia in CDI patients treated with desmopressin,^[@ref37])^ and it is safe to start the treatment with a low dose of desmopressin.

The treatment of adipsic CDI patients is challenging. The recommended treatment is as below. The ideal BW for water balance should be determined based on the serum Na levels (BW is considered to be ideal when serum Na levels are within normal ranges), but this could vary over time and should be assessed periodically. The basal volume of water intake (for example, 1 liter/day) and the required dose of desmopressin (for example, 60 µg ODT desmopressin twice a day) to maintain the ideal BW should also be determined. However, one should recall that BW could substantially change from day to day in patients, and the scale of water intake must be set based on the BW changes. For example, if the BW is 58 kg in adipsic CDI patients whose ideal BW has been determined to be 60 kg, 2 kg water has been lost. In this situation, 2 liters of water should be consumed in addition to the basal volume (1 liter) of daily water intake; that would mean that patients must drink 3 liters of water on the day, but it could be difficult for adipsic patients to consume such a volume of water, given that they do not sense thirst.

PROGNOSIS
=========

The prognosis of CDI due to tumors or inflammation depends on that of the primary diseases. On the other hand, the prognosis of idiopathic CDI patients is considered to be comparable to that of subjects without CDI, as long as the patients can drink water as necessary. However, the adipsic CDI patients are associated with significant morbidity,^[@ref38])^ and the incidence of serious infections requiring hospitalization and the risk of death have been shown to be higher in adipsic compared to non-adipsic CDI patients.^[@ref3])^

CONCLUSION
==========

The etiology has been clarified in most CDI patients. While most CDI patients are well treated with desmopressin, controlling water balance in adipsic CDI patients is still difficult.
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